Skip to main content

Protecting You From Public Health Threats

Our mission is to protect and enhance life

Emergent BioSolutions

Prepare. Prevent. Protect.

video link

We make medical countermeasures that address natural, accidental and intentional public health threats. Our products target biological and chemical threats, as well as emerging infectious diseases. 

Strengthening Our Anthrax Franchise

Emergent BioSolutions Completes Acquisition of Raxibacumab from GlaxoSmithKline

Expanding Our Portfolio of Medical Countermeasures

Emergent BioSolutions Completes Acquisition of ACAM2000 Vaccine Business from Sanofi

BioThrax, the Only FDA Licensed Anthrax Vaccine

HHS Issues Contract Actions Worth Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile

NuThrax, Our Next Generation Anthrax Vaccine

BARDA Awards Contract for Advanced Development and Delivery of NuThrax Valued at Up to $1.6 Billion


Explore more stories Scroll down